Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Investing Activities (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Cash from Investing Activities data on record, last reported at -$80.7 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 690.59% year-over-year to -$80.7 million; the TTM value through Dec 2025 reached -$8.6 million, up 83.22%, while the annual FY2025 figure was -$8.6 million, 83.22% up from the prior year.
  • Cash from Investing Activities reached -$80.7 million in Q4 2025 per CCCC's latest filing, down from $4.1 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $57.7 million in Q3 2023 and bottomed at -$100.6 million in Q3 2021.
  • Average Cash from Investing Activities over 5 years is -$1.6 million, with a median of $11.5 million recorded in 2022.
  • Peak YoY movement for Cash from Investing Activities: plummeted 33448.91% in 2021, then soared 2422.22% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$59.4 million in 2021, then soared by 115.63% to $9.3 million in 2022, then skyrocketed by 244.09% to $31.9 million in 2023, then crashed by 57.21% to $13.7 million in 2024, then tumbled by 690.59% to -$80.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$80.7 million in Q4 2025, $4.1 million in Q3 2025, and $38.9 million in Q2 2025.